Bristol Myers Squibb's Sotyktu Receives FDA Approval for Expanded Use in Psoriasis Therapy

Bristol Myers Squibb's Sotyktu has received FDA approval for the treatment of adults with psoriatic arthritis. This label expansion is supported by clinical trials demonstrating the drug's effectiveness in reducing inflammation and improving symptoms. Sotyktu is a tyrosine kinase inhibitor, and its approval marks a significant advancement in the treatment of psoriatic arthritis.